The effect of oral supplementation of Paricalcitol on C-reactive protein levels in chronic kidney disease patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials.
Journal Information
Full Title: BMC Pharmacol Toxicol
Abbreviation: BMC Pharmacol Toxicol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Ethical approvalNot applicable. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding No funding has been received by the researchers of this study."
Protocol Registration
Evidence found in paper:
"This review was conducted based on the guidelines of Prisma for systematic review and meta-analysis []. Before this, the protocol for conducting this systematic review and meta-analysis had been registered in the Prospero database with the registration number: CRD42023405139."
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025